Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$26.79
$0.58(1.96%)
At close: 4:00 PM EDT
$26.79
$0.58(1.96%)
Day’s Range― - ―
52-Week Range$19.13 - $42.21
Previous Close$30.22
Volume948.74K
Average Volume (3M)1.67M
Market Cap
$2.40B
Enterprise Value$3.55B
Total Cash (Recent Filing)$633.85M
Total Debt (Recent Filing)$82.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 11, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding119,537,170
10 Day Avg. Volume1,487,438
30 Day Avg. Volume1,673,931
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue497.95
Enterprise Value/Gross Profit540.37
Enterprise Value/Ebitda-13.91
Forecast
1Y Price Target
$53.00Price Target Upside97.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$30.26M
Bulls Say, Bears Say
Bulls Say
EU Regulatory Clearance And Commercialization ProgressEU authorization is a durable commercialization milestone that reduces regulatory risk for obicetrapib and enables partner-led market access. The associated milestone payments and tiered royalties can improve funding capacity while establishing the lead asset in the cholesterol-lowering market.
Low Leverage And Substantial Equity CushionMinimal debt and substantial equity provide financial flexibility as the company advances costly clinical and regulatory programs. The low leverage profile limits interest and refinancing pressure, allowing more capital to remain available for development and commercialization activities.
Expansion Of Obicetrapib Into Neurodegenerative DiseaseThe SPINOZA trial expands obicetrapib beyond cardiovascular disease and could broaden the lead asset’s therapeutic and commercial opportunity if biomarker and cognitive results are supportive. The approximately 400-person randomized design creates a meaningful development catalyst over coming quarters.
Bears Say
Severe Losses And Sharply Declining RevenueThe combination of very low and volatile revenue with a large net loss shows that current operations are far from supporting the cost base. Persistent unprofitability can constrain strategic flexibility and makes future progress heavily dependent on successful development and commercialization execution.
Sustained Operating And Free Cash Flow BurnLarge recurring cash outflows indicate that the business is not yet self-funding its operations or development pipeline. Continued burn increases the importance of external funding, milestone receipts, or successful commercialization, and could reduce financial flexibility if these sources are delayed.
Capital Is Currently Funding Losses Rather Than Generating ReturnsNegative returns on equity show that the substantial capital base is not currently producing earnings for shareholders. Until revenue scales or costs decline, additional investment may continue to support development losses rather than create operating returns, weakening capital efficiency.
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $19.13 and its highest was $42.20 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $2.40B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Nov 11, 2026 which is in 11 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Aug 05, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.043.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.5.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 119,537,170 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -0.472%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.00 (97.84% Upside)
$53.00 (97.84% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 67%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.19%
12-Months-Change
Fundamentals
Return on Equity
-38.33%
Trailing 12-Months
Asset Growth
-13.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$53.00
▲(97.84% Upside)
Technical Analysis
Viking Therapeutics
―
Disc Medicine
―
Structure Therapeutics, Inc. Sponsored ADR
―
MBX Biosciences, Inc.
―
Kailera Therapeutics, Inc.
―
Ownership Overview
0.37% Insiders
21.62% Mutual Funds
0.28% Other Institutional Investors
75.74% Public Companies and
Individual Investors